Kymriah® (tisagenlecleucel)
for Leukemia

Kymriah (tisagenlecleucel) is an FDA-approved gene therapy made from a patient's own white blood cells modified to include a chimeric antigen receptor (CAR). It treats relapsed/refractory acute lymphoblastic leukemia (ALL) in patients up to 25 years old, and large B-cell and follicular lymphoma in adults by targeting cancer cells to slow or stop their growth.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Leukemia